Allergan wins less than $50000 in case against compounder Imprimis
Reuters-May 17, 2019
... compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan's dry eye drug Restasis, according to a lawyer for Imprimis
No comments:
Post a Comment